Researchers at the Institute of Process Engineering, Chinese Academy of Sciences, introduced a ferritin‑based aggregation cell engager (FACE) that augments CAR‑T cell avidity without re‑engineering receptors. FACE binds CD71 on both CAR‑T cells and leukemia cells to physically bridge the two and improve killing even when target antigen expression is low; results were reported in Cell. In patient‑derived xenograft models, FACE enabled comparable efficacy using one‑fifth of the cell dose and appeared to reduce cytokine release syndrome risk. The platform is composed of endogenous ferritin and FDA‑approved polymer derivatives and can be integrated into existing manufacturing workflows as a culture supplement before infusion. Authors say the approach tackles antigen escape mechanistically rather than by altering CAR constructs.